Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Octreotide | Lanreotide |
|---|---|---|
| Class | Somatostatin analogue | Somatostatin analogue |
| Research category | acromegaly and neuroendocrine tumours | acromegaly and neuroendocrine tumours |
| Evidence level | High | High |
| Overall status | Approved (Rx) — acromegaly and neuroendocrine tumours | Approved (Rx) — acromegaly and neuroendocrine tumours |
| FDA | Approved (Rx) | Approved (Rx) |
| EMA | Approved (Rx) | Approved (Rx) |
| WADA | Check current list | Check current list |
| Mechanism studied | Octreotide → SSTR2 / SSTR5 → GH & hormone secretion ↓ → IGF-1 ↓ | Lanreotide → SSTR2 / SSTR5 → Hormone secretion ↓ → Tumour growth endpoints |
| Molecular weight | 1,019.2 g/mol | 1,096.3 g/mol |
| Sizes in stock | Not currently listed | Not currently listed |
Where the research overlaps
Both compounds are studied within Endocrine research. Octreotide is classed as somatostatin analogue, while Lanreotide is somatostatin analogue. Evidence is rated high for Octreotide and high for Lanreotide.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.